Teva Pharmaceutical has released the final data from its PEARL study, confirming that AJOVY (fremanezumab) remains effective and safe over a two-year period for individuals suffering from chronic and episodic migraines.
Consistent Reduction in Migraine Episodes
The PEARL study, encompassing 1,140 European patients, revealed that AJOVY significantly decreased the frequency, duration, and severity of migraine attacks. More than two-thirds of episodic migraine patients and over half of chronic migraine sufferers experienced a meaningful reduction in monthly migraine days during the initial six months, with benefits maintained throughout the study.
High Adherence and Robust Safety Profile
Patient adherence to AJOVY injections remained high, around 90%, with over 75% of participants completing the full two-year study. The treatment was well-tolerated, and no new safety concerns emerged, aligning with previous findings and supporting its use for long-term migraine prevention.
- Significant decrease in migraine days sustained over two years.
- High adherence rates indicate patient satisfaction and ease of use.
- Robust safety profile supports long-term treatment viability.
- Real-world evidence enhances confidence in AJOVY’s clinical benefits.
The study highlights the sustained benefits of AJOVY in real-world settings, reinforcing its role as a reliable option for migraine prevention. The high completion and adherence rates underscore its practicality and acceptance among patients.
Teva Pharmaceutical continues to lead in innovative migraine treatments with AJOVY. Healthcare providers can consider AJOVY as a long-term preventive therapy for patients with chronic or episodic migraines, backed by comprehensive real-world data. Patients experiencing frequent migraines should consult their healthcare professionals about AJOVY as a potential treatment option to enhance their quality of life.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
